Complete financial analysis of Cannabis Strategic Ventures (NUGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cannabis Strategic Ventures, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- AMBO AGRITEC LIMITED (AMBOAGRI.BO) Income Statement Analysis – Financial Results
- Shanghai Luoman Lighting Technologies Inc. (605289.SS) Income Statement Analysis – Financial Results
- Nama Chemicals Company (2210.SR) Income Statement Analysis – Financial Results
- Zurich Insurance Group AG (ZFSVF) Income Statement Analysis – Financial Results
- Shin-Etsu Chemical Co., Ltd. (SHECF) Income Statement Analysis – Financial Results
Cannabis Strategic Ventures (NUGS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cannabisstrategic.com
About Cannabis Strategic Ventures
Cannabis Strategic Ventures engages in the cultivation of marijuana products in the United States. It incubates, develops, and partners within the cannabis and ancillary sectors. The company is based in Los Angeles, California.
Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 9.85M | 14.60M | 2.37M | 701.97K | 344.70K | 0.00 | 0.00 | 149.56K | 372.11K |
Cost of Revenue | 8.93M | 11.81M | 1.89M | 680.92K | 96.03K | 0.00 | 0.00 | 122.35K | 298.00K |
Gross Profit | 921.73K | 2.78M | 476.87K | 21.05K | 248.68K | 0.00 | 0.00 | 27.21K | 74.11K |
Gross Profit Ratio | 9.35% | 19.06% | 20.14% | 3.00% | 72.14% | 0.00% | 0.00% | 18.19% | 19.92% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 4.70M | 18.22K | 96.84K | 14.59K | 17.92K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 813.00 | 6.98K |
SG&A | 8.14M | 8.08M | 7.44M | 21.14M | 4.70M | 18.22K | 96.84K | 15.40K | 24.90K |
Other Expenses | 0.00 | 0.00 | -461.46K | -319.62K | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 8.14M | 8.08M | 7.44M | 21.14M | 4.70M | 18.22K | 96.84K | 15.40K | 24.90K |
Cost & Expenses | 17.07M | 19.89M | 9.33M | 21.82M | 4.79M | 18.22K | 96.84K | 137.75K | 322.90K |
Interest Income | 0.00 | 321.09 | 0.00 | 2.76K | 13.12K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 1.36M | 0.00 | 41.22K | 0.00 | 922.00 | 0.00 | 343.00 | 0.00 | 0.00 |
Depreciation & Amortization | 1.54M | 132.18K | 132.18K | 13.01K | -104.19K | 343.00 | 343.00 | 0.00 | 0.00 |
EBITDA | -5.70M | -5.02M | -8.91M | -21.43M | -5.58M | 85.97K | -1.89M | 11.81K | 49.21K |
EBITDA Ratio | -57.81% | -34.40% | -308.07% | -3,008.08% | -1,287.26% | 0.00% | 0.00% | 7.90% | 13.22% |
Operating Income | -7.22M | -5.30M | -8.58M | -21.12M | -4.45M | -18.22K | -97.18K | 11.81K | 49.21K |
Operating Income Ratio | -73.26% | -36.30% | -362.30% | -3,008.08% | -1,291.04% | 0.00% | 0.00% | 7.90% | 13.22% |
Total Other Income/Expenses | -1.38M | -340.81K | -502.67K | -316.86K | 3.83M | 104.19K | 23.40K | 0.00 | 0.00 |
Income Before Tax | -8.60M | -5.64M | -9.08M | -21.43M | -617.25K | 85.97K | -73.78K | 11.81K | 49.21K |
Income Before Tax Ratio | -87.25% | -38.64% | -383.53% | -3,053.22% | -179.07% | 0.00% | 0.00% | 7.90% | 13.22% |
Income Tax Expense | 0.00 | 0.00 | -444.47K | 0.00 | 1.88K | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | -8.60M | -5.64M | -9.06M | -21.43M | -619.13K | 85.97K | -73.78K | 11.81K | 49.21K |
Net Income Ratio | -87.25% | -38.64% | -382.51% | -3,053.22% | -179.61% | 0.00% | 0.00% | 7.90% | 13.22% |
EPS | -0.03 | -0.02 | -0.04 | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -0.03 | -0.02 | -0.04 | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 312.13M | 272.58M | 247.73M | 268.38M | 193.28M | 21.97M | 18.77M | 6.37M | 0.00 |
Weighted Avg Shares Out (Dil) | 312.13M | 272.58M | 247.73M | 268.38M | 193.28M | 21.97M | 18.77M | 6.37M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports